急性缺血性脑卒中静脉注射替罗非班与标准药物治疗的疗效和安全性对比:随机对照试验荟萃分析

IF 1.8 4区 医学 Q3 CLINICAL NEUROLOGY Clinical Neurology and Neurosurgery Pub Date : 2024-10-25 DOI:10.1016/j.clineuro.2024.108602
{"title":"急性缺血性脑卒中静脉注射替罗非班与标准药物治疗的疗效和安全性对比:随机对照试验荟萃分析","authors":"","doi":"10.1016/j.clineuro.2024.108602","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Tirofiban is a fast-acting glycoprotein IIb-IIIa inhibitor that inhibits the final common pathway to platelet aggregation and has been studied as adjuvant therapy for acute ischemic stroke (AIS). Since the prior meta-analysis new randomized controlled trials (RCTs) have been published. This meta-analysis aimed to update the current knowledge on the efficacy of tirofiban for patients with AIS not submitted to reperfusion therapies.</div></div><div><h3>Methods</h3><div>We systematically searched <em>PubMed</em>, <em>Embase</em>, and <em>Cochrane Central Register of Controlled Trials</em> for RCTs reporting the use of tirofiban in AIS. The efficacy outcomes were favorable functional outcome, functional disability, modified Rankin Scale change at 90 days, and changes in the National Institutes of Health Stroke Scale score after 24 hours and 7 days of the symptom onset. The safety outcomes include symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), and all-cause mortality.</div></div><div><h3>Results</h3><div>A higher rate of favorable functional outcome was associated with tirofiban administration (RR= 1.09; 95 % CI 1.04–1.14; p&lt;0.001). The mRS after 90 days was significantly lower in the tirofiban group (MD= −0.55; 95 % CI −0.90 – [-0.20]; p&lt;0.01). Tirofiban administration was not significantly associated with higher rates of sICH in AIS patients (RR= 0.85; 95 % CI 0.26–2.81; p = 0.79) or any ICH compared to the control group (RR= 1.01; 95 % CI 0.42–2.39; p = 0.98). All-cause mortality was similar between groups (RR= 0.64; 95 % CI 0.34–1.23; p = 0.18).</div></div><div><h3>Conclusion</h3><div>Tirofiban increases the number of patients achieving a favorable functional outcome in patients. There was no improvement in NIHSS after 24 hours and 7 days. Tirofiban did not increase the risk of sICH or any ICH, and mortality was similar between groups.</div></div>","PeriodicalId":10385,"journal":{"name":"Clinical Neurology and Neurosurgery","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: A meta-analysis of randomized controlled trials\",\"authors\":\"\",\"doi\":\"10.1016/j.clineuro.2024.108602\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Tirofiban is a fast-acting glycoprotein IIb-IIIa inhibitor that inhibits the final common pathway to platelet aggregation and has been studied as adjuvant therapy for acute ischemic stroke (AIS). Since the prior meta-analysis new randomized controlled trials (RCTs) have been published. This meta-analysis aimed to update the current knowledge on the efficacy of tirofiban for patients with AIS not submitted to reperfusion therapies.</div></div><div><h3>Methods</h3><div>We systematically searched <em>PubMed</em>, <em>Embase</em>, and <em>Cochrane Central Register of Controlled Trials</em> for RCTs reporting the use of tirofiban in AIS. The efficacy outcomes were favorable functional outcome, functional disability, modified Rankin Scale change at 90 days, and changes in the National Institutes of Health Stroke Scale score after 24 hours and 7 days of the symptom onset. The safety outcomes include symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), and all-cause mortality.</div></div><div><h3>Results</h3><div>A higher rate of favorable functional outcome was associated with tirofiban administration (RR= 1.09; 95 % CI 1.04–1.14; p&lt;0.001). The mRS after 90 days was significantly lower in the tirofiban group (MD= −0.55; 95 % CI −0.90 – [-0.20]; p&lt;0.01). Tirofiban administration was not significantly associated with higher rates of sICH in AIS patients (RR= 0.85; 95 % CI 0.26–2.81; p = 0.79) or any ICH compared to the control group (RR= 1.01; 95 % CI 0.42–2.39; p = 0.98). All-cause mortality was similar between groups (RR= 0.64; 95 % CI 0.34–1.23; p = 0.18).</div></div><div><h3>Conclusion</h3><div>Tirofiban increases the number of patients achieving a favorable functional outcome in patients. There was no improvement in NIHSS after 24 hours and 7 days. Tirofiban did not increase the risk of sICH or any ICH, and mortality was similar between groups.</div></div>\",\"PeriodicalId\":10385,\"journal\":{\"name\":\"Clinical Neurology and Neurosurgery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Neurology and Neurosurgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S030384672400489X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurology and Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S030384672400489X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:替罗非班是一种快速起效的糖蛋白 IIb-IIIa 抑制剂,可抑制血小板聚集的最终共同途径,已被研究作为急性缺血性中风(AIS)的辅助疗法。自上次荟萃分析以来,又有新的随机对照试验(RCT)发表。本荟萃分析旨在更新关于替罗非班对未接受再灌注治疗的 AIS 患者疗效的现有知识。方法我们系统检索了 PubMed、Embase 和 Cochrane Central Register of Controlled Trials 中报告替罗非班用于 AIS 的 RCT。疗效结果包括良好的功能预后、功能障碍、90天时改良Rankin量表的变化以及症状发作24小时后和7天后美国国立卫生研究院卒中量表评分的变化。安全性结果包括症状性颅内出血(sICH)、任何颅内出血(ICH)和全因死亡率。结果 使用替罗非班可提高功能良好率(RR= 1.09;95 % CI 1.04-1.14;p<0.001)。替罗非班组 90 天后的 mRS 显著降低(MD= -0.55;95 % CI -0.90 - [-0.20];p<0.01)。与对照组(RR= 1.01;95 % CI 0.42-2.39;p = 0.98)相比,服用替罗非班与 AIS 患者 sICH 发生率升高(RR= 0.85;95 % CI 0.26-2.81;p = 0.79)或任何 ICH 发生率升高无明显相关性。各组的全因死亡率相似(RR= 0.64; 95 % CI 0.34-1.23; p = 0.18)。24小时和7天后NIHSS没有改善。替罗非班不会增加 sICH 或任何 ICH 的风险,各组死亡率相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: A meta-analysis of randomized controlled trials

Introduction

Tirofiban is a fast-acting glycoprotein IIb-IIIa inhibitor that inhibits the final common pathway to platelet aggregation and has been studied as adjuvant therapy for acute ischemic stroke (AIS). Since the prior meta-analysis new randomized controlled trials (RCTs) have been published. This meta-analysis aimed to update the current knowledge on the efficacy of tirofiban for patients with AIS not submitted to reperfusion therapies.

Methods

We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for RCTs reporting the use of tirofiban in AIS. The efficacy outcomes were favorable functional outcome, functional disability, modified Rankin Scale change at 90 days, and changes in the National Institutes of Health Stroke Scale score after 24 hours and 7 days of the symptom onset. The safety outcomes include symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), and all-cause mortality.

Results

A higher rate of favorable functional outcome was associated with tirofiban administration (RR= 1.09; 95 % CI 1.04–1.14; p<0.001). The mRS after 90 days was significantly lower in the tirofiban group (MD= −0.55; 95 % CI −0.90 – [-0.20]; p<0.01). Tirofiban administration was not significantly associated with higher rates of sICH in AIS patients (RR= 0.85; 95 % CI 0.26–2.81; p = 0.79) or any ICH compared to the control group (RR= 1.01; 95 % CI 0.42–2.39; p = 0.98). All-cause mortality was similar between groups (RR= 0.64; 95 % CI 0.34–1.23; p = 0.18).

Conclusion

Tirofiban increases the number of patients achieving a favorable functional outcome in patients. There was no improvement in NIHSS after 24 hours and 7 days. Tirofiban did not increase the risk of sICH or any ICH, and mortality was similar between groups.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Neurology and Neurosurgery
Clinical Neurology and Neurosurgery 医学-临床神经学
CiteScore
3.70
自引率
5.30%
发文量
358
审稿时长
46 days
期刊介绍: Clinical Neurology and Neurosurgery is devoted to publishing papers and reports on the clinical aspects of neurology and neurosurgery. It is an international forum for papers of high scientific standard that are of interest to Neurologists and Neurosurgeons world-wide.
期刊最新文献
Tirofiban vs. aspirin in patients with acute ischemic stroke: A meta-analysis of randomized clinical trials Editorial Board Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: A meta-analysis of randomized controlled trials Patient-completed online “follow-up form” to assess continuation of anti-CGRP(r) antibody therapy in patients with chronic migraine: A pilot study Analysis of the impact of a rhinologist-assisted endoscopic approach on a single neurosurgeon’s outcomes in transsphenoidal resection of pituitary adenomas
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1